| **DRUG, SPONSOR, TYPE OF SUBMISSION** | **DRUG TYPE OR USE** | **LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION** | **PBAC OUTCOME** |
| --- | --- | --- | --- |
| BUDESONIDE WITH EFORMOTEROL, Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dehydrate 6 micrograms per dose, 120 doses;  Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dehydrate 12 micrograms per dose, 2 x 60 doses  DuoResp® Spiromax®, Teva Pharma Australia Pty Ltd  Symbicort Turbuhaler®, AstraZeneca Pty Ltd | Asthma  COPD | To amend the restrictions for:  •200/6: asthma (both brands);  •400/12: asthma and COPD (both brands)  So that both products have the same Authority Required (Streamlined) code. | The PBAC recommended amending the currently listed budesonide with formoterol 200/6 and 400/12 restrictions for asthma and chronic obstructive pulmonary disease (COPD) to enable these restrictions to have identical Authority Required (Streamlined) codes.  See also November 2017 PBAC outcomes. |
| MENINGOCOCCAL POLYSACCHARIDE SEROGROUPS A, C, W-135 AND Y CONJUGATE VACCINE  Injection 0.5 mL in pre-filled syringe  Nimenrix®  Pfizer Australia Pty Ltd  Further consideration  (Major Submission) | Meningococcal disease | To consider a revised proposal for request listing on the National Immunisation Program (NIP) for the immunisation of adolescents in Year 10 and a catch-up program for adolescents aged up to 19 years administered via a school or GP-based catch up program. | The PBAC revised its March 2018 recommendation for meningococcal polysaccharide serogroups A, C, W135 and Y conjugate vaccine (MenACWY-TT) and advised that the MenACWY-TT vaccine would be acceptably cost-effective at a price that results in a cost/QALY gained of $15,000-45,000 or less would be acceptable in the context of the relatively small cost of the primary program.  See also March 2018 PBAC outcomes. |